Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupDermatologic OncologyradiotherapyDiseaseMerkel Cell CarcinomaSubgroupSomatostatin receptor positiveICD10C44.9MeSHCarcinoma, Merkel CellSequenceCRBP2/Radiation followed by CRBP 4.5/ETOP80, MCC, part A (PID109) -|- CRBP2/Radiation followed by CRBP 4.5/ETOP80, MCC, part B (PID1111)ChemotherapyChemo-substanceAvelumabCarboplatinCisplatinEtoposideIpilimumabNivolumabOctreotidePaclitaxelPembrolizumabChemo-substanceAvelumabCarboplatinCisplatinEtoposideIpilimumabNivolumabOctreotidePaclitaxelPembrolizumabChemo-substanceAvelumabCarboplatinCisplatinEtoposideIpilimumabNivolumabOctreotidePaclitaxelPembrolizumabChemo-substanceAvelumabCarboplatinCisplatinEtoposideIpilimumabNivolumabOctreotidePaclitaxelPembrolizumabNo. Substances123 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideNo. Substances1234567Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseneoadjuvantTherapy intentioncurativepalliativeRisksAdrenal InsufficiencyAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaCardiotoxicityCholelithiasisColitisConstipationDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHyperbilirubinemiaHyperglycemiaHyperthyroidismHyponatremiaHypotensionHypothyroidismIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaMyocarditisNauseaNeutropeniaPancreatitisPneumonitisPruritusRashRenal FailureThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorAkaike TCancer Care OntarioKaufmann HKim SNghiem PPoulsen MTopalian SL DiseaseChemotherapierefraktäres Merkelzellkarzinomfortgeschrittenes MerkelzellkarzinomMerkellzellkarzinom, nicht operabelMerkelzellkarzinomMerkelzellkarzinom, ECOG 0-2Merkelzellkarzinom, resektabel, ECOG 0-1Merkelzellkarzinom, Stadium IV, nicht resektabel, rezidiviert, auch nach Therapie mit PD-1- oder PD-L1-InhibitorenOriginCancer Care Ontario, Drug Formulary, RegimenDepartment of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USADepartment of Medicine, University of Washington, Seattle, WA, USADivision of Cancer Services, Princess Alexandra Hospital,University of QueenslandDivision of Cancer Services, Princess Alexandra Hospital, University of QueenslandRutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USASidney Kimmel Comprehensive Cancer Center, Baltimore, MD, CheckMate 358 studyUniversity of Washington Medical Center Protocols in Revision 13 protocols foundProtocols under revision.Avelumab 800, Merkel Cell Carcinoma (PID1076 V2.2)Carboplatin 2 / Radiation followed by Carboplatin 4.5 / Etoposide 80, Merkel Cell Carcinoma Part B (PID1111 V1.0)Carboplatin 2 / Radiation followed by Carboplatin 4.5, Etoposide 80, Merkel Cell Carcinoma Part A (PID109 V1.0)Carboplatin 5 / Etoposide 100, Merkel Cell Carcinoma (PID1107 V1.0)Cisplatin 25 / Etoposide 100, Merkel Cell Carcinoma (PID1108 V1.1)Etoposide (50/100) / Paclitaxel 200 / Carboplatin 5, Merkel Cell Carcinoma (PID117 V1.1)Etoposide 100, Merkel Cell Carcinoma (PID116 V1.0)Etoposide 50, Merkel Cell Carcinoma (PID115 V1.0)Nivolumab 240 / Ipilimumab 1, Merkel Cell Carcinoma (PID2414 V1.0)Nivolumab 240, Merkel Cell Carcinoma, neoadjuvant (PID2413 V1.0)Octreotide LAR 30, Merkel Cell Carcinoma (PID2415 V1.0)Pembrolizumab 200, Merkel Cell Carcinoma, first-line (PID1285 V1.1)Pembrolizumab 200, Merkel Cell Carcinoma, second-line (PID1078 V2.1)
